Publicacions en què col·labora amb Eva Bandres Elizalde (4)

2011

  1. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

2010

  1. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  2. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis

    British Journal of Cancer, Vol. 102, Núm. 6, pp. 987-994

2009

  1. Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients

    EJC SUPPLEMENTS